Institut Pasteur biotech spin-off Oncovita and Unither Pharmaceuticals have announced plans to develop and produce a new combined prophylactic vaccine for the prevention of infectious diseases in children. This collaboration combines Measovir, Oncovita’s platform designed to develop highly immunogenic vaccines, with Euroject, Unither Pharmaceuticals’ Blow-Fill-Seal (BFS)-based single-dose injection system for the direct administration of vaccines […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!